ContraFect Corporation
CFRX
|
$0.05
0.0%
910K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-97.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2396.14% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 535,240
http://www.contrafect.com
Sec Filling | Patents | 24 employees
(US) ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
antibody monoclonal antibodies infectious disease influenza treatment bloodstream injection
add to watch list Paper trade email alert is off
Press-releases
Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology, Corp.’; Athersys, Inc.; Borqs Technologies, Inc.; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition Corp.; Evelo Biosciences, Inc.; Troika Media Group, Inc.; Impel Pharmaceuticals Inc.; Fresh Tracks Therapeutics, Inc.; and Near Intelligence, Inc. from The Nasdaq Stock Market
Published: 2023-12-26 (Crawled : 21:00) - globenewswire.com
SDCCQ | $0.004 -20.0% 54K
|
n/a
|
| O: -28.75%
H: 40.35%
C: 15.79%
NDAQ | $60.075 0.11% 0.11% 2.3M
|
Finance
|
| O: -0.07%
H: 0.75%
C: 0.69%
CWBR | $0.9003 -11.88% 360
|
Health Technology
|
| O: 0.0%
H: 5.11%
C: 5.11%
nasdaq media acquisition pharmaceuticals market
Global Antibiotic Resistance Market Research Report 2023-2027: Search for Alternatives to Antibiotics Creates New Goldrush
Published: 2023-10-27 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -2.35%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
ENTA | $13.23 -5.5% -5.82% 150K
|
Health Technology
|
| O: -0.36%
H: 1.07%
C: -0.71%
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: -0.41%
H: 2.04%
C: -7.79%
ARDS | $0.066 2.82% 28K
|
Health Technology
|
| O: 16.05%
H: 1.06%
C: -7.98%
report antibiotics research global market
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyCF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: 17.89%
H: 0.0%
C: -29.19%
cf-370 fda clearance application trial pathogens
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
Published: 2023-09-19 (Crawled : 12:00) - globenewswire.com
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: -9.23%
H: 1.69%
C: -3.73%
drug conference
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
Published: 2023-09-18 (Crawled : 12:00) - globenewswire.com
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: 15.66%
H: 0.0%
C: 0.0%
cf-370 fda candidate application submission
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
Published: 2023-08-28 (Crawled : 12:00) - globenewswire.com
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: -4.25%
world
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-08-14 (Crawled : 12:20) - globenewswire.com
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: 4.71%
H: 0.0%
C: -4.01%
business update financial results
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
Published: 2023-06-27 (Crawled : 12:20) - globenewswire.com
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: -3.7%
H: 13.08%
C: 11.54%
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
Published: 2023-06-20 (Crawled : 13:00) - globenewswire.com
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: 1.69%
H: 2.76%
C: -5.52%
pathogens platform
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
Published: 2023-06-08 (Crawled : 20:00) - globenewswire.com
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: 25.0%
H: 22.78%
C: 7.78%
pathogens potential
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10